tiprankstipranks
Trending News
More News >
Surgery Partners Inc (SGRY)
NASDAQ:SGRY
US Market
Advertisement

Surgery Partners (SGRY) Earnings Dates, Call Summary & Reports

Compare
367 Followers

Earnings Data

Report Date
Mar 02, 2026
Before Open (Confirmed)
Period Ending
2025 (Q4)
Consensus EPS Forecast
0.3
Last Year’s EPS
0.44
Same Quarter Last Year
Moderate Buy
Based on 11 Analysts Ratings

Earnings Call Summary

Q3 2025
Earnings Call Date:Nov 10, 2025|
% Change Since:
|
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture with solid revenue and EBITDA growth, strong performance in surgical cases, and significant capital deployment in growth areas. However, the company faces challenges with softer than expected volume growth, unfavorable payer mix changes, delayed capital deployment, and regulatory delays impacting new facilities. These challenges have led to a revision in full-year guidance.
Company Guidance
During the third quarter of 2025, Surgery Partners reported net revenue of $821.5 million, marking a 6.6% increase year over year. The company achieved an adjusted EBITDA of $136.4 million, a 6.1% rise compared to the previous year, with an adjusted EBITDA margin of 16.6%. Same facility revenue grew by 6.3%, and the company completed over 166,000 surgical cases, exhibiting 2.1% growth. Notably, total joint surgeries in Ambulatory Surgery Center (ASC) facilities increased by 16% in the third quarter and 23% year-to-date. Despite these positive metrics, the company revised its full-year guidance, anticipating revenue between $3.275 billion and $3.3 billion and adjusted EBITDA between $535 million and $540 million, due to a softer-than-expected volume growth and payer mix changes, particularly a decline in commercial payers to 50.6% of revenues. Additionally, Surgery Partners deployed $71 million for acquisitions, divested interest in three ASCs at a combined enterprise value of $50 million, and maintained a robust M&A pipeline exceeding $300 million.
Revenue and EBITDA Growth
Net revenue was $821.5 million, up 6.6% year over year. Adjusted EBITDA was $136.4 million, up 6.1% year over year, with an adjusted EBITDA margin of 16.6%.
Strong Surgical Case Growth
The company performed over 166,000 surgical cases in the third quarter, representing a 2.1% growth. Significant growth in orthopedic procedures, with total joint surgeries in ASC facilities growing 16% in the third quarter and 23% year-to-date.
Capital Deployment in Growth
Approximately $71 million deployed for acquisitions, with a robust M&A pipeline of over $300 million in opportunities under active evaluation.
De Novo Facility Expansion
Two new de novo facilities opened in the third quarter, with nine under construction and more than a dozen in the development pipeline, primarily focused on higher acuity specialties like orthopedics.
Cost Management and Efficiency
Supply costs were down 70 basis points, and G&A expenses were reduced, reflecting lower stock-based and incentive-based compensation.

Surgery Partners (SGRY) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

SGRY Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Mar 02, 2026
2025 (Q4)
0.30 / -
0.44
Nov 10, 2025
2025 (Q3)
0.20 / 0.13
0.19-31.58% (-0.06)
Aug 05, 2025
2025 (Q2)
0.18 / 0.17
0.21-19.05% (-0.04)
May 12, 2025
2025 (Q1)
0.07 / 0.04
0.1-60.00% (-0.06)
Mar 03, 2025
2024 (Q4)
0.38 / 0.44
0.440.00% (0.00)
Nov 12, 2024
2024 (Q3)
0.25 / 0.19
0.190.00% (0.00)
Aug 06, 2024
2024 (Q2)
0.20 / 0.21
0.28-25.00% (-0.07)
May 07, 2024
2024 (Q1)
0.07 / 0.10
0.0825.00% (+0.02)
Feb 26, 2024
2023 (Q4)
0.38 / 0.44
0.2762.96% (+0.17)
Nov 07, 2023
2023 (Q3)
0.14 / 0.19
-0.021050.00% (+0.21)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

SGRY Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 10, 2025
$21.50$16.04-25.40%
Aug 05, 2025
$22.22$22.14-0.36%
May 12, 2025
$22.16$23.26+4.96%
Mar 03, 2025
$24.08$24.00-0.33%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Surgery Partners Inc (SGRY) report earnings?
Surgery Partners Inc (SGRY) is schdueled to report earning on Mar 02, 2026, Before Open (Confirmed).
    What is Surgery Partners Inc (SGRY) earnings time?
    Surgery Partners Inc (SGRY) earnings time is at Mar 02, 2026, Before Open (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is SGRY EPS forecast?
          SGRY EPS forecast for the fiscal quarter 2025 (Q4) is 0.3.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis